Premium
Antiosteoporotic effects of 3:1 (g/g) mixed formulation of exopolymers purified from Aureobasidium pullulans SM‐2001 and Dendropanax morbifera leaf extracts in ovariectomized rats
Author(s) -
Cho ChangSoo,
Jeong HyeSeong,
Kim InYoung,
Jung GoWoon,
Ku BonHwa,
Park DongChan,
Moon SeungBae,
Cho HyungRae,
Ku Sae Kwang,
Choi JaeSuk
Publication year - 2018
Publication title -
journal of food biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.507
H-Index - 47
eISSN - 1745-4514
pISSN - 0145-8884
DOI - 10.1111/jfbc.12548
Subject(s) - ovariectomized rat , osteoporosis , bone mineral , aureobasidium pullulans , medicine , endocrinology , bone remodeling , chemistry , femur , biochemistry , fermentation , estrogen , surgery
The dose‐dependent antiosteoporotic potentials of the exopolymers from Aureobasidium pullulans (EAP): Dendropanax morbifera (DM) 3:1 (g/g) were observed in bilateral ovariectomized (OVX) rats. Twenty‐eight days after bilateral OVX surgery, 200 mg/kg EAP or DM, and 400, 200, and 100 mg/kg EAP : DM (3:1) were orally administered, once a day for 56 days. We measured changes in body weight and weight gain, bone weight, length, thickness, strength, and bone mineral density and contents. Additionally, histological profiles and histomorphometric analyses of serum biochemistry and urine biochemistry were conducted at sacrifice. Femur, tibia, and the 4th or 5th lumbar vertebrae were sampled, and histomorphometry of bone mass, structure, and resorption were also performed. In this study, the findings suggest that EAP : DM (3:1) synergistically increased the distinct antiosteoporotic potentials of the single formulations of EAP and DM in OVX rats, suggesting a promising new potent protective agent for relieving osteoporosis in menopausal women. Practical applications Osteoporosis is a metabolic bone disease characterized by decreased bone strength, leading to increased risk of fractures. EAP have antiosteoporotic activity and DM has various health beneficial effects including immunological enhancement. We hypothesized that appropriated mixtures consisting of EAP and DM leaf extracts (EAP : DM) will show more favorable synergistic antiosteoporotic effects due to increases in the diversity of bioactive ingredients. In the present study, rats treated with 200 mg/kg of EAP : DM 3:1 (g/g) showed significantly more favorable inhibitory activity against estrogen‐deficient osteoporosis symptoms induced by OVX compared with those treated with 200 mg/kg of EAP or DM. Therefore, EAP : DM 3:1 (g/g) may be a promising new potent protective agent for relieving osteoporosis in menopausal women.